SCHEMBL14744893

SCHEMBL14744893

Cc1c(O)cc(=O)[nH]c1-c1ccc2cn(C)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.44
KDM4E B2RXH2 2/20 0.42
NSD2 O96028 1/20 0.42
ALDH1A1 P00352 1/20 0.42
BRD4 O60885 3/20 0.40
CREBBP Q92793 2/20 0.40
JAK3 P52333 3/20 0.39
JAK2 O60674 2/20 0.39
SCD5 Q86SK9 1/20 0.36
MAPK1 P28482 2/20 0.35
POLQ O75417 1/20 0.35
NOTUM Q6P988 1/20 0.35
MAT2A P31153 1/20 0.33
ADAM17 P78536 1/20 0.33
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KDM4C Q9H3R0 1/20 0.32
CTSC P53634 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16428767 0.90 KDM4E (0.39) MAPTKDM4ENOTUMMAT2A
SCHEMBL14745065 0.84 MAPT (0.41) MAPTKDM4ENSD2ALDH1A1BRD4
SCHEMBL14741104 0.77 MAPT (0.40) MAPTKDM4ENSD2ALDH1A1BRD4
SCHEMBL16428747 0.76 ERCC1 (0.56) BRD4SCD5NOTUM
SCHEMBL16428837 0.74 CHRM1 (0.38) KDM4EMAT2A
SCHEMBL16428746 0.73 ERCC1 (0.44) BRD4CREBBP
SCHEMBL16568205 0.68 PGR (0.43) MAPTKDM4EALDH1A1NOTUMHPGD
SCHEMBL14741043 0.68 JAK2 (0.39) MAPTKDM4ENSD2ALDH1A1BRD4
SCHEMBL14741117 0.68 MAT2A (0.36) KDM4EMAPK1NOTUMMAT2AKDM4C
SCHEMBL22946640 0.67 KDM4E (0.61) MAPTKDM4ENSD2ALDH1A1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP MAPT 4110/4885KDM4E 4305/4885NSD2 3980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.